Impact of COVID-19 on the elderly: from lung aging to defense mechanisms: an integrative literature review
from lung aging to defense mechanisms - an integrative literature review
DOI:
https://doi.org/10.47456/rbps.v27i1.40644Keywords:
Elderly, Lung Injury, SARS-CoV-2Abstract
Introduction: Elderly people were primarily the population most affected by the Pandemic of COVID-19, representing about 8.7% of deaths in the period from 2020 to 2022. Objective: To understand the impact of COVID-19 on the lung of the elderly, its clinical manifestations and the main defense mechanisms. Methods: Integrative literature review with an active search for information in the following databases: PubMed (National Library of Medicine), MEDLINE (Medical Literature Analysis and Retrieval System), Science Direct, Scielo (Scientific Electronic Library Online) and Portal de Periódico Capes/MEC, with bibliographic production between 2020 and 2022, based on the descriptors: "Elderly", "SARS-CoV-2", "Lung", based on the Health Sciences Descriptors (DeCS) using the booster element "AND". Review studies published in the period from 2020 to 2022 with older adults with a mean age ≥ 65 years were included, by articles with casuistries addressed outside Brazil, of both sexes, COVID-19 (SARS-CoV-2). The search was limited to English language publications and literature review articles and the methodology followed the PRISMA recommendations. Results: We identified ten (10) articles that met the inclusion criteria, (7) articles from the Science Direct database, two (2) from CAPES, and one (1) from PubMed. Conclusion: The progression of COVID-19 in the elderly population is due to the physiological and structural changes of the senescent lung, increasing the risk of Acute Respiratory Distress Syndrome (ARDS), exacerbating the clinical picture and making the elderly body more vulnerable to secondary infections with imminent risk of death.
Downloads
References
Paradella R. Número de idosos cresce 18% em 5 anos e ultrapassa 30 milhões em 2017 [Internet]. Agência IBGE Notícias; 2018 [citado em 7 jul 2022]. Disponível em: https://agenciadenoticias.ibge.gov.br/agencia-noticias/2012-agencia-de-noticias/noticias/20980-numero-de-idosos-cresce-18-em-5-anos-e-ultrapassa-30-milhoes-em-2017
Oliveira DV, et al. Epidemiologia do envelhecimento. In: Oliveira DV, et al., organizadores. Educação Física em Gerontologia. Curitiba: Appris; 2021. cap. 1-2.
Araujo GB, et al. Impacto da pandemia de Covid-19 na saúde do idoso: um estudo a partir de artigos originais da Brazilian Journal of Geriatrics and Gerontology. RECIMA21. 2021;2(9):e29780.
Oliveira OD, et al. Prevalência e fatores associados à vulnerabilidade em idosos: uma revisão. Rev Enferm Atual In Derme. 2021;95(34).
Instituto Butantan. Qual a diferença entre SARS-CoV-2 e COVID-19? Prevalência e incidência são a mesma coisa? E mortalidade e letalidade? [Internet]. São Paulo: Instituto Butantan; 2021 [citado em 10 jul 2022]. Disponível em: https://butantan.gov.br/covid/butantan-tira-duvida/tira-duvida-noticias/qual-a-diferenca-entre-sars-cov-2-e-covid-19-prevalencia-e-incidencia-sao-a-mesma-coisa-e-mortalidade-e-letalidade
Liu K, et al. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14-e18.
Smorenberg A, et al. How does SARS-CoV-2 target the elderly patients? A review on potential mechanisms increasing disease severity. Eur J Intern Med. 2021;83:1-5.
Lemos CEG, et al. O sistema respiratório na COVID-19. In: Silva CGL, Gadelha MSV, organizadores. SARS-CoV-2: uma ameaça invisível em tempos líquidos, a jornada de um vírus à luz da patologia. Juazeiro do Norte: Universidade Federal do Cariri; 2020. cap. 4.
Lima T, et al. Previsão de óbito e importância de características clínicas em idosos com COVID-19 utilizando o Algoritmo Random Forest. Rev Bras Saude Mater Infant. 2021;21(Supl 2).
Ritchie H, et al. Mortes por Coronavírus (COVID-19) [Internet]. Our World in Data; 2022 [citado em 7 jul 2022]. Disponível em: https://ourworldindata.org/covid-deaths
Paula AS, et al. Desfechos clínicos dos idosos hospitalizados com COVID-19. Res Soc Dev. 2022;11(2).
Ercole FF, et al. Revisão integrativa versus revisão sistemática. Rev Min Enferm. 2014;18(1):9-12.
Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.
Al-Zahrani J. SARS-CoV-2 associated COVID-19 in geriatric population: a brief narrative review. Saudi J Biol Sci. 2021;28(1):738-743.
Jergović M, et al. Immune response to COVID-19 in older adults. J Heart Lung Transplant. 2021;40(10):1082-1089.
Farshbafnadi M, et al. Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: the role of entangled risk factors. Exp Gerontol. 2021;154:111507.
Gallo A, et al. How can biology of aging explain the severity of COVID-19 in older adults. Clin Geriatr Med. 2022;38(3):461-472.
Polidori CM, et al. COVID-19 mortality as a fingerprint of biological age. Ageing Res Rev. 2021;67:101308.
To KKW, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-574.
Pujadas E, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8(9):e70.
Nehme J, et al. Cellular senescence as a potential mediator of COVID-19 severity in the elderly. Aging Cell. 2020;19(10):e13237.
Naylor K, et al. The influence of age on T cell generation and TCR diversity. J Immunol. 2005;174(11):7446-7452.
Wang W, et al. Thymic aging may be associated with COVID-19 pathophysiology in the elderly. Cells. 2021;10(3):628.
Yang Y, et al. COVID-19 in elderly adults: clinical features, molecular mechanisms, and proposed strategies. Aging Dis. 2020;11(6):1481.
Schneider JL, et al. The aging lung: physiology, disease, and immunity. Cell. 2021;184(8):1990-2019.
Pascotini FS, et al. Força muscular respiratória, função pulmonar e expansibilidade toracoabdominal em idosos e sua relação com o estado nutricional. Fisioter Pesqui. 2016;23:416-422.
Bailey KL, et al. Oxidative stress associated with aging activates protein kinase Cε, leading to cilia slowing. Am J Physiol Lung Cell Mol Physiol. 2018;315(5):L882-L890.
Witkowski JM, Fulop T, Bryl E. Immunosenescence and COVID-19. Mech Ageing Dev. 2022;204:111672.
Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-535.
Ghasemzadeh M, Ghasemzadeh A, Hosseini E. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. Hum Immunol. 2022 Jan;83(1):86-98.
Kim KS, et al. Interferon-γ induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells. Mech Ageing Dev. 2009;130(3):179-188.
Acosta JC, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):978-990.
Kandhaya-Pillai R, et al. TNFα-senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion. Aging (Albany NY). 2017;9(11):2411.
Gao KM, et al. Human nasal wash RNA-Seq reveals distinct cell-specific innate immune responses in influenza versus SARS-CoV-2. JCI Insight. 2021;6(22).
Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Tang D, et al. The hallmarks of COVID-19 disease. PLoS Pathog. 2020;16(5):e1008536.
Wanhella KJ, Fernandez-Patron C. Biomarkers of ageing and frailty may predict COVID-19 severity. Ageing Res Rev. 2022;73:101513.
Jain S, et al. An account of immune senescence in the clinical pathophysiology of COVID-19 infection in aging. Aging Dis. 2021;12(2):662.
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
